Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

被引：21

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
]}

Myint, Zin W. ^{[3
]}

Iacovelli, Roberto ^{[4
]}

Pichler, Martin ^{[5
]}

Basso, Umberto ^{[6
]}

Kopecky, Jindrich ^{[7
]}

Kucharz, Jakub ^{[8
]}

Buti, Sebastiano ^{[9
]}

Rizzo, Mimma ^{[10
]}

Galli, Luca ^{[11
]}

Buettner, Thomas ^{[12
]}

De Giorgi, Ugo ^{[13
]}

Kanesvaran, Ravindran ^{[14
]}

Fiala, Ondrej ^{[15
]}

Grande, Enrique ^{[16
]}

Zucali, Paolo Andrea ^{[17
,18
]}

Fornarini, Giuseppe ^{[19
]}

Bourlon, Maria T. ^{[20
]}

Scagliarini, Sarah ^{[21
]}

Molina-Cerrillo, Javier ^{[22
]}

Aurilio, Gaetano ^{[23
]}

Matrana, Marc R. ^{[24
]}

Pichler, Renate ^{[25
]}

Cattrini, Carlo ^{[26
]}

Buechler, Tomas ^{[27
]}

Seront, Emmanuel ^{[28
]}

Calabro, Fabio ^{[29
]}

Pinto, Alvaro ^{[30
]}

Berardi, Rossana ^{[31
]}

Zgura, Anca ^{[32
]}

Mammone, Giulia ^{[33
]}

Ansari, Jawaher ^{[34
]}

Atzori, Francesco ^{[35
]}

Chiari, Rita ^{[36
]}

Bamias, Aristotelis ^{[37
]}

Caffo, Orazio ^{[38
]}

Procopio, Giuseppe ^{[39
,40
]}

Bassanelli, Maria ^{[41
]}

Merler, Sara ^{[42
]}

Messina, Carlo ^{[43
]}

Kueronya, Zsofia ^{[44
]}

Mosca, Alessandra ^{[45
]}

Bhuva, Dipen ^{[46
]}

Vau, Nuno ^{[47
]}

Incorvaia, Lorena ^{[48
]}

Rebuzzi, Sara Elena ^{[49
,50
]}

Roviello, Giandomenico ^{[51
]}

Zabalza, Ignacio Ortego ^{[16
]}

Rizzo, Alessandro ^{[52
]}

机构：

[1] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol Med, Rome, Italy

[5] Med Univ Graz, Dept Internal Med, Div Oncol, Augenbruggerplatz 15, A-8010 Graz, Austria

[6] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Oncol Unit 3, Padua, Italy

[7] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove, Czech Republic

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Uro Oncol, Warsaw, Poland

[9] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[10] AOU Consorziale Policlin Bari, Div Med Oncol, Piazza G Cesare 11, I-70124 Bari, Italy

[11] Univ Hosp Pisa, Oncol Unit 2, I-56126 Pisa, Italy

[12] Univ Hosp Bonn UKB, Dept Urol, D-53127 Bonn, Germany

[13] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Meldola, Italy

[14] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[15] Charles Univ Prague, Univ Hosp Pilsen, Fac Med, Dept Oncol & Radiotherapeut, Plzen, Czech Republic

[16] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[17] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Milan, Italy

[18] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[19] IRCCS Osped Policlin San Martino, Genoa, Italy

[20] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Oncol Dept, Mexico City, Mexico

[21] Azienda Osped Rilievo Nazl Cardarelli Napoli, UOC Oncol, Naples, Italy

[22] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[23] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[24] Ochsner Med Ctr, Dept Internal Med, Hematol Oncol, New Orleans, LA USA

[25] Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria

[26] Maggiore Car Univ Hosp, Dept Med Oncol, I-28100 Novara, Italy

[27] Charles Univ Prague, Thomayer Univ Hosp, Fac Med 1, Dept Oncol, Prague 14059, Czech Republic

[28] Ctr Hospitalier Jolimont, Dept Med Oncol, Haine St Paul, Haine Saint Paul, Belgium

[29] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[30] La Paz Univ Hosp, Med Oncol Dept, Madrid, Spain

[31] Univ Politecn Marche, Dept Med Oncol, AOU Ospedali Riuniti Marche, Ancona, Italy

[32] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[33] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Viale Regina Elena 324, I-00185 Rome, Italy

[34] Tawam Hosp, Med Oncol, Al Ain, U Arab Emirates

[35] Azienda Osped Univ Cagliari, Unita Oncol Med, Cagliari, Italy

[36] Azienda Osped Ospedali Riuniti Marche Nord, UOC Oncol, Tuscany, Italy

[37] Natl & Kapodistrian Univ Athens, ATTIKON Univ Hosp, Sch Med, Propaedeut Dept Internal Med 2, Athens, Greece

[38] Santa Chiara Hosp, Med Oncol Unit, Trento, Italy

[39] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Med, Milan, Italy

[40] Osped Maggiore Cremona, Oncol Med, Cremona, Italy

[41] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[42] Univ Verona, Verona Univ Hosp Trust, Dept Med, Sect Oncol,Sch Med, Verona, Italy

[43] ARNAS Civ, Oncol Unit, Palermo, Italy

[44] Natl Inst Oncol, Dept Genitourinary Med Oncol & Clin Pharmacol, Budapest, Hungary

[45] IRCCS FPO, Candiolo Canc Inst, Oncol, I-10060 Turin, Italy

[46] Army Hosp Res & Referral, Dept Med Oncol, New Delhi, India

[47] Champalimaud Clin Ctr, Urol Oncol, P-1400038 Lisbon, Portugal

[48] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[49] Osped San Paolo, Med Oncol, I-17100 Savona, Italy

[50] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

来源：

TARGETED ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

CYTOREDUCTIVE NEPHRECTOMY; SUNITINIB; CANCER;

D O I：

10.1007/s11523-023-00978-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.

引用

页码：559 / 570

页数：12

共 50 条

[1] Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Santoni, Matteo
Massari, Francesco
Myint, Zin W.
Iacovelli, Roberto
Pichler, Martin
Basso, Umberto
Kopecky, Jindrich
Kucharz, Jakub
Buti, Sebastiano
Salfi, Alessia
Buettner, Thomas
De Giorgi, Ugo
Kanesvaran, Ravindran
Fiala, Ondrej
Grande, Enrique
Zucali, Paolo Andrea
Fornarini, Giuseppe
Bourlon, Maria T.
Scagliarini, Sarah
Molina-Cerrillo, Javier
Aurilio, Gaetano
Matrana, Marc R.
Pichler, Renate
Cattrini, Carlo
Buechler, Tomas
Seront, Emmanuel
Calabro, Fabio
Pinto, Alvaro
Berardi, Rossana
Zgura, Anca
Mammone, Giulia
Ansari, Jawaher
Atzori, Francesco
Chiari, Rita
Zakopoulou, Roubini
Caffo, Orazio
Procopio, Giuseppe
Bassanelli, Maria
Zampiva, Ilaria
Messina, Carlo
Kueronya, Zsofia
Mosca, Alessandra
Bhuva, Dipen
Vau, Nuno
Incorvaia, Lorena
Rebuzzi, Sara Elena
Roviello, Giandomenico
Zabalza, Ignacio Ortego
Rizzo, Alessandro
Mollica, Veronica
CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : E309 - U12
[2] Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy
Ueda, K. O. S. U. K. E.
Suekane, S. H. I. G. E. T. A. K. A.
Kurose, H. I. R. O. F. U. M. I.
Ito, N. A. O. K. I.
Ogasawara, N. A. O. Y. U. K., I
Hiroshige, T. A. S. U. K. U.
Chikui, K. A. T. S. U. A. K., I
Ejima, K. A. Z. U. H. I. S. A.
Uemura, K. E. I. I. C. H. I. R. O.
Nakiri, M. A. K. O. T. O.
Nishihara, K. I. Y. O. A. K. I.
Matsuo, M. I. T. S. U. N. O. R. I.
Igawa, T. S. U. K. A. S. A.
ANTICANCER RESEARCH, 2022, 42 (09) : 4573 - 4580
[3] Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Massari, Francesco
Mollica, Veronica
Fiala, Ondrej
De Giorgi, Ugo
Kucharz, Jakub
Vitale, Maria Giuseppa
Molina-Cerrillo, Javier
Facchini, Gaetano
Seront, Emmanuel
Lenci, Edoardo
Bourlon, Maria T.
Carrozza, Francesco
Pichler, Renate
Lolli, Cristian
Myint, Zin W.
Kanesvaran, Ravindran
Torniai, Mariangela
Rescigno, Pasquale
de Liano, Alfonso Gomez
Zakopoulou, Roubini
Buti, Sebastiano
Porta, Camillo
Grande, Enrique
Santoni, Matteo
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1123 - 1131
[4] Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy
Mehra, Ranee
Huang, Huan
Seal, Brian
Tse, Jenny
Shenolikar, Rahul A.
Burudpakdee, Chakkarin
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (08): : 2030 - 2038
[5] The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma
Parreira, Sara
Burns, Kathleen
Moldawer, Nancy
Zomordian, Nazy
Bandali, Nesan
Virdee, Kiran
Walsh, Meghara
Kelly, Daniel
Rao, Dharanija
Teresi, Rosemary
Wood, Laura S.
SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
[6] Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma
Ramakrishnan, Karthik
Liu, Zhiwen
Baxi, Shrujal
Chandwani, Sheenu
Joo, Sam
Chirovsky, Diana
FUTURE ONCOLOGY, 2021, 17 (23) : 3037 - 3050
[7] Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study
Hall, Jennifer P.
Zanotti, Giovanni
Kim, Ruth
Krulewicz, Stan P.
Leith, Andrea
Bailey, Abigail
Liu, Frank X.
Kearney, Mairead
FUTURE ONCOLOGY, 2020, 16 (36) : 3045 - 3060
[8] Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma
Esterberg, Elizabeth
Iyer, Shrividya
Nagar, Saurabh P.
Davis, Keith L.
Tannir, Nizar M.
CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 115 - 125.e3
[9] Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
Graham, Jeffrey
Shah, Amishi Y.
Wells, J. Connor
McKay, Rana R.
Vaishampayan, Ulka
Hansen, Aaron
Donskov, Frede
Bjarnason, Georg A.
Beuselinck, Benoit
De Velasco, Guillermo
Iafolla, Marco
Duh, Mei S.
Huynh, Lynn
Chang, Rose
Zanotti, Giovanni
Ramaswamy, Krishnan
Choueiri, Toni K.
Tannir, Nizar M.
Heng, Daniel Y. C.
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (01): : 102 - 111
[10] Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma
Ishikawa, Gaku
Tamura, Keita
Tsuchiya, Yoshihiro
Watanabe, Shunsuke
Ayana, Takemura
Asuka, Sano
Watanabe, Kyohei
Watanabe, Hiromitsu
Matsushita, Yuto
Motoyama, Daisuke
Otsuka, Atsushi
Inamoto, Teruo
ANTICANCER RESEARCH, 2025, 45 (01) : 379 - 386

← 1 2 3 4 5 →